Skip to content

Public FDA record

Z-0618-2019: VITEK 2 Antimicrobial Susceptibility Testing (AST) using one or more of these susceptibility products: Ca

Recall record Z-0618-2019 for bioMerieux, Inc.. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0618-2019
Company in FDA record
bioMerieux, Inc.
FDA record creation date
Dec 17, 2018
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

False resistant results for Streptococcus anginosus and Streptococcus constellatus strains were reported.

Source facts

Action
The Firm, Biomerieux, issued a " URGENT Product Correction Notice" to their consignees informing of the matter and providing certain actions for them to take. Each Notice will be accompanied with an Acknowledge Form which is to be returned to bioMerieux.. The consignees were instructed to take the following action at this time: " Please confirm this letter has been distributed and reviewed by all appropriate personnel within your organization. " Reference your Laboratory Standard Operating Procedures to identify card types and breakpoints used in your facility to determine if your laboratory is impacted by the issue described in this letter. " Reference your Laboratory Standard Operating Procedures to identify if retrospective analysis is required for reported results associated with the referenced limitation. " For systems utilizing EUCAST breakpoints and operating with VITEK 2 Systems Software version 8.01, create a bioART Rule for the referenced limitation associated with Ceftriaxone (cro01n). " Please store this letter with your bioMrieux instrument documentation. -Please complete the attached Acknowledgement Form (Attachment A) and return it to bioMrieux, Inc. If you have any questions or concerns, please contact your local bioMrieux representative or call , Regulatory Quality Compliance Specialist, at 314-731-8805 or email: debra.broyles@biomerieux.com.
Initiated
2018-10-22
Root cause
Component change control
Terminated
2019-11-04
Distribution
Worldwide Distribution: US (nationwide) to states of: AK, AL, AR, AZ, CA, CO, CT, DC, FL, GA, HI, IA, ID, IL, IN, KS, KY, LA, MA, MD, ME, MI, MN, MO, MS, MT, NC, ND, NE, NH, NJ, NM, NY, NV, OH, OK, OR, PA, RI, SC, SD, TN, TX, VA, VT, WA, WI, WV, WY including Puerto Rico and to countries of:Algeria, Angola, Azerbaijan, Bahrain, Bangladesh, Belarus, Sarl, Benin, Bosnia-Herz, Cameroon, Chad, Cote d'Ivoire, Croatia, Dem. Rep. Congo, Egypt, , Georgia, Guam, Ethiopia, Iraq, Jordan, Kazakhstan, Kenya, Kuwait, Latvia, Lebanon, UAB, Lithuania, Macedonia, Malta, Mongolia, Morocco, Mozambique, Niger, Oman, Pakistan, Palestine, Qatar, Romania, Saudi Arabia, Senegal, Serbia, Slovenia, Sri Lanka, Tunisia, Ukraine, Gabon, and Zimbabwe.
Recall number
Z-0618-2019
Recall status
Terminated
CDRH record ID
168666
FDA record created
2018-12-17
Recall event number
81415

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗